Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers

Affiliations

¹ Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Institute of Stroke and Cerebrovascular Disease, University of Texas Health Science Center at Houston, Houston, TX, USA.
³ Institutional Analytics & Informatics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Cardtronics, Inc, Houston, TX, USA.
⁵ Core for Biomolecular Structure and Function, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁷ Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Pharmaceutical Science Facility, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁹ Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
¹⁰ Director of Drug Discovery and Development, Advanced Organic Synthesis LLC, Houston, Texas, USA.
¹¹ Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹² Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹³ Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA. aettius@aol.com.

Published Erratum

Yu-Hsi Lin et al. Nat Metab. 2021 Jan.

. 2021 Jan;3(1):122.

doi: 10.1038/s42255-020-00335-x.

¹ Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Institute of Stroke and Cerebrovascular Disease, University of Texas Health Science Center at Houston, Houston, TX, USA.
³ Institutional Analytics & Informatics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Cardtronics, Inc, Houston, TX, USA.
⁵ Core for Biomolecular Structure and Function, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁷ Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Pharmaceutical Science Facility, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁹ Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
¹⁰ Director of Drug Discovery and Development, Advanced Organic Synthesis LLC, Houston, Texas, USA.
¹¹ Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹² Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹³ Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA. aettius@aol.com.

No abstract available

Erratum for

An enolase inhibitor for the targeted treatment of ENO1-deleted cancers.
Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, Mandal P, Sun Y, Zielinski R, Pando SC, Wang X, Tran T, Xu Q, Wu Q, Jiang Y, Kang Z, Asara JM, Priebe W, Bornmann W, Marszalek JR, DePinho RA, Muller FL. Lin YH, et al. Nat Metab. 2020 Dec;2(12):1413-1426. doi: 10.1038/s42255-020-00313-3. Epub 2020 Nov 23. Nat Metab. 2020. PMID: 33230295 Free PMC article.